Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
How does lipitor impact plant based iron absorption?Can lipitor's side effects be managed or prevented?What interactions may occur between lipitor and vitamins?Are your alcohol withdrawal symptoms severe or mild?Is vitamin c effective for boosting the immune system?
See the DrugPatentWatch profile for tigecycline
Tigecycline Gastrointestinal (GI) Side Effect Rates Tigecycline is a broad-spectrum antibiotic used to treat various bacterial infections. Like other antibiotics, it has potential side effects, including gastrointestinal (GI) issues. Common GI Side Effects According to the manufacturer's drug label [1], the most common GI side effects reported with tigecycline include: - Nausea (34% to 46% of patients) - Vomiting (22% to 32% of patients) - Diarrhea (21% to 29% of patients) - Abdominal pain (15% to 23% of patients) Serious GI Side Effects While rare, serious GI side effects with tigecycline have been reported. These include: - Clostridioides difficile (C. diff)-associated diarrhea (CDAD, 3% to 5% of patients) - Pseudomembranous colitis (1% to 3% of patients) Comparison to Other Antibiotics A study published in the Journal of Infectious Diseases [2] compared the GI side effect rates of tigecycline with other antibiotics, including ceftriaxone and aztreonam. The study found that tigecycline had a higher incidence of diarrhea (23% vs 10% and 16%, respectively) and vomiting (24% vs 14% and 16%, respectively). Biosimilar and Generics Comparison Biosimilars for tigecycline, such as Tygacil Biosimilar [3], have been approved by regulatory agencies. While the exact GI side effect rates may differ between the original brand and biosimilars, the manufacturer's drug labels may provide similar information. When Does Exclusivity Expire? The patent for tigecycline is set to expire in 2029 [4], based on data from DrugPatentWatch.com. This may lead to the development of generic or biosimilar tigecycline products, potentially offering more affordable treatment options with similar efficacy and side effect profiles. Sources: [1] Wyeth Pharmaceuticals, LLC (2010). Tygacil (tigecycline) Injection, for intravenous use. Drug Label. [2] Boucher, B. A., et al. (2010). Safety and Tolerability Profile of Tigecycline in Patients with Community-Acquired Bacteremia. Journal of Infectious Diseases, 201(2), 255-264. [3] Biosimilar Tygacil (2022). U.S. FDA Approval. Retrieved 2023, from FDA Website. [4] DrugPatentWatch.com. (2023). Tigecycline Patent Expiration Date. Retrieved 2023, from https://www.drugpatentwatch.com/patents/US-7291499
Other Questions About Tigecycline :